Autolus Therapeutics (AUTL) AI Stock Analysis

• Market Cap: $508.33M
• Dividend Yield: N/A
• Average Volume (3M): 2.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: 407.86%
• EPS Growth: 30.35%
• Country: US
• Employees: 647
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.30
• Shares Outstanding: 266,143,280
• 10 Day Avg. Volume: 2,430,183
• 30 Day Avg. Volume: 2,370,614
• PEG Ratio: 0.10
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 59.25
• P/FCF Ratio: -2.49
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 7.63
• Enterprise Value/Gross Profit: -2.47
• Enterprise Value/Ebitda: -1.55
• 1Y Price Target: $7.93
• Price Target Upside: 315.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $2.00 ▲(4.71% Upside)

The score is held back primarily by weak profitability and negative cash flow despite improving revenue, while technicals are supportive with strong momentum but overbought signals. Earnings-call execution on the Obe-cel launch is a positive driver, but high cost of sales and continued losses temper the outlook; valuation is constrained by negative earnings.

Positive Factors

Revenue Growth

Significant revenue growth indicates strong market demand and successful product adoption, enhancing long-term business prospects.

Market Penetration

Increased market penetration suggests robust competitive positioning and potential for sustained growth in the CAR T therapy market.

Leadership Strength

New board member with commercial experience can enhance strategic direction and execution, supporting long-term growth and expansion.

Negative Factors

Profitability Challenges

Ongoing profitability issues highlight operational inefficiencies, which could hinder long-term financial sustainability and growth.

High Cost of Sales

Excessive cost of sales relative to revenue suggests inefficiencies that could pressure margins and limit future profitability.

Operational Losses

Continued operational losses reflect financial challenges that may require strategic adjustments to achieve long-term viability.

Autolus Therapeutics Business Overview & Revenue Model

Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Autolus Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for research and development activities in exchange for rights to commercialize products developed from Autolus' technology. Additionally, the company may receive milestone payments as its product candidates progress through clinical trials and regulatory approvals. While Autolus is primarily in the development phase and may not yet have substantial product sales, revenue can also be derived from licensing agreements and grants to support its ongoing research initiatives.

Autolus Therapeutics Financial Statement Overview

Summary

Autolus Therapeutics shows strong revenue growth but struggles with profitability and cash flow. The balance sheet is solid with low leverage and substantial cash reserves, yet operational losses and negative cash flows are significant challenges.

Income Statement

Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.

Balance Sheet

The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.

Cash Flow

Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	51.13M	10.12M	1.70M	6.19M	1.51M	1.72M
Gross Profit	-158.22M	-130.90M	1.70M	6.19M	1.51M	-133.17M
EBITDA	-250.91M	-233.07M	-156.77M	-132.24M	-132.47M	-162.58M
Net Income	-224.80M	-220.66M	-208.38M	-148.84M	-142.10M	-142.09M
Balance Sheet
Total Assets	661.95M	782.73M	375.38M	490.27M	405.56M	294.24M
Cash, Cash Equivalents and Short-Term Investments	367.41M	588.02M	239.57M	382.44M	310.34M	154.09M
Total Debt	65.83M	52.63M	52.97M	24.26M	68.01M	54.16M
Total Liabilities	396.50M	355.40M	263.91M	191.60M	92.24M	84.20M
Stockholders Equity	265.45M	427.32M	111.47M	298.67M	313.32M	210.03M
Cash Flow
Free Cash Flow	-278.04M	-241.09M	-156.57M	-123.15M	-126.72M	-132.44M
Operating Cash Flow	-254.18M	-206.27M	-145.59M	-112.31M	-117.86M	-117.76M
Investing Cash Flow	-311.67M	-394.55M	-10.99M	-10.84M	-8.86M	-14.68M
Financing Cash Flow	27.46M	589.55M	-883.00K	223.61M	284.06M	74.42M

Autolus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.91
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Positive. The current price of 1.91 is above the 20-day moving average (MA) of 1.74, above the 50-day MA of 1.54, and above the 200-day MA of 1.72, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 61.51 is Neutral, neither overbought nor oversold. The STOCH value of 75.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUTL.

Autolus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUTL	54 Neutral	$508.33M	-2.26	-60.52%	―	407.86%	30.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTNM	50 Neutral	$334.98M	-4.07	-30.40%	―	―	-100.71%
DMAC	49 Neutral	$434.85M	-11.64	-64.12%	―	―	-29.73%
BNTC	48 Neutral	$412.44M	-12.11	-43.71%	―	―	80.95%
LRMR	47 Neutral	$287.58M	-1.74	-78.24%	―	―	-67.41%
TVRD	38 Underperform	$39.68M	-0.43	-97.61%	―	-53.67%	86.75%

Autolus Therapeutics Corporate Events

Autolus Therapeutics Appoints Ryan Richardson to Board

On December 1, 2025, Autolus Therapeutics announced the appointment of Ryan Richardson as a Class I director on its Board of Directors. Mr. Richardson, who has over 20 years of experience in healthcare and investment banking, previously served as Chief Strategy Officer at BioNTech SE, where he played a significant role in the company’s global expansion and transition to a commercial stage. His expertise is expected to aid Autolus in its growth as a commercial-stage company, particularly in expanding the reach of its therapy, obe-cel, in new indications.

The most recent analyst rating on (AUTL) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Autolus Therapeutics Appoints New Principal Accounting Officer

On November 7, 2025, Autolus Therapeutics announced the resignation of Rob Dolski as Principal Accounting Officer, with Patrick McIlvenny appointed to the role effective the same day. The company reported third-quarter 2025 financial results, including $21.1 million in net product revenue for AUCATZYL® and 60 authorized treatment centers. Autolus is advancing its obe-cel therapy for pediatric r/r B-ALL and severe lupus nephritis, with promising clinical data and FDA designations supporting further trials. Leadership changes aim to bolster commercial growth and operational efficiency.

The most recent analyst rating on (AUTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.